Immucor appoints new CEO as De Chirico retires
This article was originally published in Clinica
Gioacchino De Chirico is retiring from his role as president and CEO of blood screening firm Immucor after 18 years with the company. He will be immediately replaced by Joshua Levine, who was most recently president and CEO of aesthetic medical device developer Mentor; Mentor was acquired by Johnson & Johnson in 2009 (www.clinica.co.uk, 19 January 2009). Mr Levine has also worked for Kinetic Concepts, American Hospital Supply Corporation, and Baxter International. During his tenure, Dr De Chirico guided Norcross, Georgia-based Immucor through several scandals: in 2009, the FDA threatened to revoke its biologics licence over concerns about its manufacturing processes (www.clinica.co.uk, 30 June 2009); the company was also investigated for potential anti-competitive practices (www.clinica.co.uk, 28 April 2009).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.